Research programme: AMPK activators - Mercury Therapeutics

Drug Profile

Research programme: AMPK activators - Mercury Therapeutics

Alternative Names: AMPK activators - Mercury Therapeutics; Debio 0930; Debio-0930B; MT 47100

Latest Information Update: 16 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dartmouth College
  • Developer Debiopharm Group; Mercury Therapeutics
  • Class Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Cardiovascular disorders; Metabolic disorders; Type 2 diabetes mellitus

Most Recent Events

  • 07 Jan 2016 Early research in Metabolic disorders in Switzerland (unspecified route) (Debiopharm Group pipeline, January 2016)
  • 21 Feb 2011 Debio 0930 is still in early research for Type 2 diabetes in Europe
  • 15 Jul 2010 Millipore has been acquired by Merck KGaA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top